Strong week for Actinogen Medical (ASX:ACW) shareholders doesn't alleviate pain of one-year loss

Simply Wall St.02-03

Actinogen Medical Limited (ASX:ACW) shareholders will doubtless be very grateful to see the share price up 89% in the last quarter. But that's not enough to compensate for the decline over the last...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2408529009?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2024-02-03 04:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2408529009","market":"us","top_or_hot":-1,"title":"Strong week for Actinogen Medical (ASX:ACW) shareholders doesn't alleviate pain of one-year loss","media":"Simply Wall St.","content":"<div>\n<p>Actinogen Medical Limited (ASX:ACW) shareholders will doubtless be very grateful to see the share price up 89% in the last quarter.    But that's not enough to compensate for the decline over the last...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/strong-week-for-actinogen-medical-asxacw-shareholders-doesnt\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Strong week for Actinogen Medical (ASX:ACW) shareholders doesn't alleviate pain of one-year loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStrong week for Actinogen Medical (ASX:ACW) shareholders doesn't alleviate pain of one-year loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-02-03 04:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/strong-week-for-actinogen-medical-asxacw-shareholders-doesnt><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Actinogen Medical Limited (ASX:ACW) shareholders will doubtless be very grateful to see the share price up 89% in the last quarter.    But that's not enough to compensate for the decline over the last...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/strong-week-for-actinogen-medical-asxacw-shareholders-doesnt\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/strong-week-for-actinogen-medical-asxacw-shareholders-doesnt","article_id":"2408529009","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2408529009","pubTimestamp":1706904130,"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Actinogen Medical Limited ( ASX:ACW ) shareholders will doubtless be very grateful to see the share price up 89% in the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","ACW.AU":"ACTINOGEN MEDICAL LTD","BK7508":"医药生物股"},"translate_title":"放线菌医疗（ASX：ACW）股东的强劲一周并没有减轻一年亏损的痛苦","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACW.AU":1},"content_text":"Actinogen Medical Limited (ASX:ACW) shareholders will doubtless be very grateful to see the share price up 89% in the last quarter.    But that's not enough to compensate for the decline over the last twelve months.  Like an arid lake in a warming world, shareholder value has evaporated, with the share price down 65% in that time.  Some might say the recent bounce is to be expected after such a bad drop.  Of course, it could be that the fall was overdone.      While the stock has risen 17% in the past week but long term shareholders are still in the red, let's see what the fundamentals can tell us.    View our latest analysis for Actinogen Medical   Given that Actinogen Medical didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development.  When a company doesn't make profits, we'd generally expect to see good revenue growth.  That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.   In the last year Actinogen Medical saw its revenue grow by 34%.   That's definitely a respectable growth rate.   Meanwhile, the share price tanked 65%, suggesting the market had much higher expectations.  It may well be that the business remains approximately on track, but its revenue growth has simply been delayed.  For us it's important to consider when you think a company will become profitable, if you're basing your valuation on revenue.       You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image). ASX:ACW Earnings and Revenue Growth February 2nd 2024 Take a more thorough look at Actinogen Medical's financial health with this free report on its balance sheet.  A Different Perspective Actinogen Medical shareholders are down 63% for the year, but the market itself is up 5.5%.  However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period.     Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 7% per year over five years.  Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround.        While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important.   Like risks, for instance. Every company has them, and we've spotted   7 warning signs for Actinogen Medical   (of which 2 are significant!) you should know about.     If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges.Valuation is complex, but we're helping make it simple.Find out whether Actinogen Medical is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2408529009"}